Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Insulin resistance7794 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A03953 | 33809062 | Mar Drugs | Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis. | 2021 | Details |
| A03958 | 33808007 | Int J Mol Sci | Momordica cochinchinensis Aril Ameliorates Diet-Induced Metabolic Dysfunction and Non-Alcoholic Fatty Liver by Modulating Gut Microbiota. | 2021 | Details |
| A03963 | 33807573 | Int J Mol Sci | An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. | 2021 | Details |
| A03968 | 33806527 | Pharmaceuticals (Basel) | The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. | 2021 | Details |
| A03970 | 33805912 | Int J Mol Sci | Potential of Nutraceutical Supplementation in the Modulation of White and Brown Fat Tissues in Obesity-Associated Disorders: Role of Inflammatory Signalling. | 2021 | Details |
| A03977 | 33804296 | J Clin Med | From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction? | 2021 | Details |
| A03983 | 33802047 | J Clin Med | Natural History of NAFLD. | 2021 | Details |
| A03990 | 33800465 | Metabolites | Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03993 | 33798787 | Cell Mol Gastroenterol Hepatol | Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver. | 2021 | Details |
| A03999 | 33794784 | BMC Gastroenterol | A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. | 2021 | Details |
| A04001 | 33794740 | Adipocyte | Swertiamarin supplementation prevents obesity-related chronic inflammation and insulin resistance in mice fed a high-fat diet. | 2021 | Details |
| A04005 | 33792864 | J Endocrinol Invest | Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets. | 2021 | Details |
| A04010 | 33790119 | Yakugaku Zasshi | [VNUT Is a Therapeutic Target for Type 2 Diabetes and NASH]. | 2021 | Details |
| A04025 | 33785339 | Life Sci | A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH. | 2021 | Details |
| A04030 | 33783746 | Adv Exp Med Biol | Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin. | 2021 | Details |
| A04031 | 33783745 | Adv Exp Med Biol | Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). | 2021 | Details |
| A04032 | 33782980 | Andrologia | Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. | 2021 | Details |
| A04045 | 33777674 | Acta Pharm Sin B | S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling. | 2020 | Details |
| A04050 | 33776471 | Int J Gen Med | The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms. | 2021 | Details |
| A04060 | 33773192 | Phytomedicine | Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. | 2021 | Details |
| A04063 | 33772456 | Indian J Gastroenterol | Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study. | 2021 | Details |
| A04064 | 33772116 | Commun Biol | INPP4B protects from metabolic syndrome and associated disorders. | 2021 | Details |
| A04067 | 33771728 | Mol Metab | Ube2i deletion in adipocytes causes lipoatrophy in mice. | 2021 | Details |
| A04069 | 33771638 | J Ethnopharmacol | Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs. | 2021 | Details |
| A04077 | 33768585 | Hepatology | Tumor Necrosis Factor α-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation. | 2021 | Details |
| A04100 | 33760189 | Mol Med Rep | Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An in vitro and in vivo study. | 2021 | Details |
| A04109 | 33754067 | Theranostics | NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin. | 2021 | Details |
| A04110 | 33753727 | Cell Death Dis | S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD. | 2021 | Details |
| A04126 | 33746906 | Front Endocrinol (Lausanne) | Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. | 2021 | Details |
| A04130 | 33746449 | J Clin Exp Hepatol | What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? | 2020 | Details |
| A04131 | 33746447 | J Clin Exp Hepatol | Study of Cellular Senescence and Vitamin D Deficiency in Nonalcoholic Fatty Liver Disease and The Potential Protective Effect of Vitamin D Supplementation. | 2020 | Details |
| A04134 | 33746082 | J Hepatol | The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. | 2021 | Details |
| A04141 | 33743554 | Hepatology | Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04146 | 33742318 | Curr Diab Rep | The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. | 2021 | Details |
| A04156 | 33736626 | BMC Endocr Disord | Calcium to magnesium intake ratio and non-alcoholic fatty liver disease development: a case-control study. | 2021 | Details |
| A04157 | 33736456 | Antioxid Redox Signal | Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk. | 2021 | Details |
| A04167 | 33731171 | Nutr Metab (Lond) | Neck circumference as an independent predictor for NAFLD among postmenopausal women with normal body mass index. | 2021 | Details |
| A04175 | 33727836 | Diabetes Metab Syndr Obes | Electromagnetic Fields Ameliorate Insulin Resistance and Hepatic Steatosis by Modulating Redox Homeostasis and SREBP-1c Expression in db/db Mice. | 2021 | Details |
| A04176 | 33727658 | Commun Biol | Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes. | 2021 | Details |
| A04177 | 33727164 | Clin Gastroenterol Hepatol | Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. | 2021 | Details |
| A04189 | 33722690 | Mol Metab | Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression. | 2021 | Details |
| A04192 | 33721354 | Clin Exp Pharmacol Physiol | Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression. | 2021 | Details |
| A04195 | 33720570 | Ter Arkh | [Clinical and prognostic value of metabolic disorders in non-alcoholic fatty liver disease]. | 2020 | Details |
| A04196 | 33720280 | Biochem J | α-Methyl-l-tryptophan as a weight-loss agent in multiple models of obesity in mice. | 2021 | Details |
| A04199 | 33719959 | Curr Pharm Des | The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. | 2021 | Details |
| A04209 | 33712680 | Sci Rep | Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma. | 2021 | Details |
| A04211 | 33711964 | BMC Pediatr | Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. | 2021 | Details |
| A04225 | 33708180 | Front Microbiol | Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. | 2021 | Details |
| A04232 | 33705650 | Diabetes Metab J | Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. | 2021 | Details |
| A04233 | 33704100 | Clin Transl Gastroenterol | Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. | 2021 | Details |
| A04245 | 33691757 | Diabetol Metab Syndr | Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. | 2021 | Details |
| A04246 | 33691721 | Nutr Metab (Lond) | Integrative proteomic and lipidomic analysis of Kaili Sour Soup-mediated attenuation of high-fat diet-induced nonalcoholic fatty liver disease in a rat model. | 2021 | Details |
| A04250 | 33689525 | Arch Physiol Biochem | Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. | 2021 | Details |
| A04254 | 33688229 | Diabetes Metab Syndr Obes | Risk Factors Screening for Gestational Diabetes Mellitus Heterogeneity in Chinese Pregnant Women: A Case-Control Study. | 2021 | Details |
| A04267 | 33684566 | Biochim Biophys Acta Mol Cell Biol Lipids | GDF11 rapidly increases lipid accumulation in liver cancer cells through ALK5-dependent signaling. | 2021 | Details |
| A04268 | 33683797 | Int J Clin Pract | The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. | 2021 | Details |
| A04271 | 33681089 | Can J Gastroenterol Hepatol | NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. | 2021 | Details |
| A04274 | 33680375 | Caspian J Intern Med | Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. | 2020 | Details |
| A04285 | 33678036 | Hum Exp Toxicol | Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. | 2021 | Details |
| A04301 | 33672073 | Nutrients | Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients. | 2021 | Details |
| A04302 | 33671926 | Int J Mol Sci | Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. | 2021 | Details |
| A04303 | 33671880 | Biomedicines | Immunomodulatory Role of Urolithin A on Metabolic Diseases. | 2021 | Details |
| A04307 | 33671547 | Int J Mol Sci | Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. | 2021 | Details |
| A04313 | 33669288 | Int J Environ Res Public Health | Relationships between Socioeconomic Status, Handgrip Strength, and Non-Alcoholic Fatty Liver Disease in Middle-Aged Adults. | 2021 | Details |
| A04317 | 33667726 | Mol Metab | Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. | 2021 | Details |
| A04318 | 33667513 | Life Sci | Exercise improves lipid droplet metabolism disorder through activation of AMPK-mediated lipophagy in NAFLD. | 2021 | Details |
| A04324 | 33665291 | Pract Lab Med | Low levels of spexin and adiponectin may predict insulin resistance in patients with non-alcoholic fatty liver. | 2021 | Details |
| A04325 | 33665203 | Front Nutr | The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories? | 2021 | Details |
| A04326 | 33665176 | Front Pediatr | Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity. | 2021 | Details |
| A04331 | 33664225 | Cell Death Dis | Hepatic HuR protects against the pathogenesis of non-alcoholic fatty liver disease by targeting PTEN. | 2021 | Details |
| A04332 | 33664007 | Arab J Gastroenterol | Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. | 2021 | Details |
| A04333 | 33662773 | Clin Res Hepatol Gastroenterol | Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease. | 2021 | Details |
| A04338 | 33658534 | Sci Rep | Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. | 2021 | Details |
| A04339 | 33658485 | Cell Death Dis | WW domain-binding protein 2 overexpression prevents diet-induced liver steatosis and insulin resistance through AMPKβ1. | 2021 | Details |
| A04340 | 33658438 | Endocr J | Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD)-a population-based study. | 2021 | Details |
| A04352 | 33652261 | Biomed Pharmacother | Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury. | 2021 | Details |
| A04354 | 33650781 | Physiol Rep | Serum fetuin-A and Ser312 phosphorylated fetuin-A responses and markers of insulin sensitivity after a single bout of moderate intensity exercise. | 2021 | Details |
| A04366 | 33647280 | Gastroenterology | Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target. | 2021 | Details |
| A04367 | 33647205 | Chem Res Toxicol | LXRα/β Antagonism Protects against Lipid Accumulation in the Liver but Increases Plasma Cholesterol in Rhesus Macaques. | 2021 | Details |
| A04386 | 33639194 | Eur J Pharmacol | Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. | 2021 | Details |
| A04395 | 33636024 | Hepatology | Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α. | 2021 | Details |
| A04418 | 33626072 | PLoS One | Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. | 2021 | Details |
| A04429 | 33618924 | Nutr Metab Cardiovasc Dis | Serum leptin as a mediator of the influence of insulin resistance on hepatic steatosis in youths with excess adiposity. | 2021 | Details |
| A04443 | 33615207 | JHEP Rep | NASH-related increases in plasma bile acid levels depend on insulin resistance. | 2020 | Details |
| A04451 | 33611063 | Int Immunopharmacol | Hyperoside attenuates non-alcoholic fatty liver disease through targeting Nr4A1 in macrophages. | 2021 | Details |
| A04458 | 33608323 | Dis Model Mech | High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition. | 2021 | Details |
| A04460 | 33608033 | Nutr Metab (Lond) | Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. | 2021 | Details |
| A04497 | 33596132 | Metab Syndr Relat Disord | When They're Done Growing, Don't Forget They May Still Need Growth Hormone. | 2021 | Details |
| A04502 | 33595214 | Isr Med Assoc J | The Impact of Ramadan Fasting on Fatty Liver Disease Severity: A Retrospective Case Control Study from Israel. | 2021 | Details |
| A04506 | 33594581 | Diabetes Ther | Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. | 2021 | Details |
| A04514 | 33592199 | Life Sci | Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. | 2021 | Details |
| A04515 | 33591626 | J Cell Mol Med | Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. | 2021 | Details |
| A04521 | 33588102 | Mol Metab | Stress kinases in the development of liver steatosis and hepatocellular carcinoma. | 2021 | Details |
| A04525 | 33586811 | J Hum Nutr Diet | Association of dietary insulinaemic potential and odds of non-alcoholic fatty liver disease among adults: A case-control study. | 2021 | Details |
| A04530 | 33586120 | Diabetes Ther | Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | 2021 | Details |
| A04535 | 33584988 | World J Hepatol | Shifting perspectives - interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. | 2021 | Details |
| A04562 | 33579423 | Adv Cancer Res | NAFLD-related HCC. | 2021 | Details |
| A04565 | 33578702 | Antioxidants (Basel) | Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. | 2021 | Details |
| A04567 | 33578449 | Biotechnol Appl Biochem | An insight into the role of telmisartan as PPAR-γ/α dual activator in the management of nonalcoholic fatty liver disease. | 2021 | Details |
| A04568 | 33578292 | Biochem Biophys Res Commun | Mesenchymal stem cell-conditioned medium improved mitochondrial function and alleviated inflammation and apoptosis in non-alcoholic fatty liver disease by regulating SIRT1. | 2021 | Details |